10-Q: eXoZymes Reports Q3 2026 Results Amidst Going Concern Doubts

eXoZymes Inc. filed its Q3 2026 Form 10-Q, detailing ongoing net losses and operational cash burn, leading to substantial doubt about its ability to continue as a going concern, despite a recent capital raise.

Summary

• eXoZymes Inc. reported its financial results for the quarter and nine months ended September 30, 2026.
• The company incurred net losses of $7,487,389 for the nine months ended September 30, 2026, and $6,503,698 for the same period in 2025.
• Operating cash burn was $5,386,342 for the nine months ended September 30, 2026, compared to $4,528,240 in the prior year.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status.
• The company completed underwritten public and registered direct offerings in June 2026, raising net proceeds of $5,861,147.
• Cash and cash equivalents increased to $3,258,901 as of September 30, 2026, from $3,039,343 as of December 31, 2025.
• Total assets decreased by 1.8% to $5,862,684 as of September 30, 2026, from $5,971,517 as of December 31, 2025.
• Total liabilities increased significantly by 42.6% to $3,671,241 as of September 30, 2026, largely due to a new warrant liability.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to the company's continued net losses, significant cash burn, and the explicit statement of substantial doubt about its ability to continue as a going concern, despite recent capital raises.

Positives

• Cash and cash equivalents increased by 7.2% to $3,258,901 as of September 30, 2026, from $3,039,343 as of December 31, 2025, reflecting proceeds from recent offerings.
• Net proceeds of $5,861,147 were raised from underwritten public and registered direct offerings in June 2026.
• Property and equipment, net, increased by 17.2% to $895,929, indicating investment in operational assets.
• Research and development costs increased by 60.9% for the nine months ended September 30, 2026, showing continued investment in innovation.
• The company has a strong intellectual property portfolio with over 30 issued patents and more than 40 pending patents.

Negatives

• The company incurred a net loss of $7,487,389 for the nine months ended September 30, 2026, and $6,503,698 for the same period in 2025.
• Operating cash burn was $5,386,342 for the nine months ended September 30, 2026, an increase from the prior year.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern.
• Total liabilities increased by 42.6% to $3,671,241 as of September 30, 2026, primarily due to a new warrant liability of $1,129,085.
• Grants receivable decreased by 58.1% to $216,923 as of September 30, 2026.
• Operating lease right-of-use asset, net, decreased by 16.2%, and finance lease right-of-use asset, net, decreased by 33.8%.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status.
• The company's ability to meet its long-term liabilities and obligations depends on securing additional financial support.
• Changes to United States tariff and import/export regulations may have an adverse effect on the business.
• Government actions on tariffs and research grants could impede the company's ability to conduct research and raise capital.
• The company's endeavors to create and bring new technologies to the market may never come to fruition or reach commercial viability.
• Technologies developed may not gain widespread or timely acceptance, or may fail to receive necessary regulatory approvals.

Future Outlook

The company's ability to continue operations and meet long-term obligations depends on securing additional financial resources or achieving profitable operations. Management is pursuing non-dilutive funding, additional offerings, institutional or bank financing, and intellectual property licensing. The company expects to achieve a self-affirmed GRAS determination for Tyferyn (NCT) in Q2 2027 and conduct a single-dose human PK study in Q1 2027.

Management Comments

• Management has concluded that the Company's existing working capital is not sufficient to fund operations for twelve months from the date these condensed unaudited consolidated financial statements are issued and that substantial doubt exists about its ability to continue as a going concern.
• The Company's ability to meet its long-term liabilities and obligations depends on securing additional financial support, whether through continued shareholder funding, raising equity or debt financing, or ultimately achieving profitable operations.
• We believe our cell-free approach removes a bottleneck that has limited cell-based synthetic biology.
• We believe this level of biosolution performance could enable new markets and business opportunities and provide us with a competitive advantage.
• We believe the Powered by eXoZymes platform can eventually make many of the molecules synthetic biology set out to make.
• We intend to pursue a fast-to-market launch first and then pharmaceutical opportunities.
• We believe our isolation and purification efforts are often much easier and lower cost compared to competing methods, as we can produce at very high purity and without the many co-products and impurities typical of fermentation or extraction from natural sources.
• We believe our approach offers at least three advantages, each of which still has to be proven at commercial scale and over time: Speed and cost, Access to rare molecules, Repeatable pathway design.

Industry Context

StockSavvy.ai notes that eXoZymes operates in the rapidly evolving synthetic biology and biomanufacturing sector, aiming to address limitations of traditional cell-based systems with its cell-free exozyme platform. The company's focus on rare, high-value molecules for health and wellness aligns with growing market interest in natural compounds and advanced therapeutics. The competitive landscape includes other companies developing novel biomanufacturing solutions, but eXoZymes' unique approach to enzyme engineering and AI-driven development may offer a differentiated path.

Comparison to Industry Standards

• The company's lead program, N-trans-caffeoyltyramine (NCT), achieved a pilot run with 99% feedstock conversion and 99.6% purity in hours, which is significantly faster and purer than typical fermentation processes, suggesting a potential advantage over industry standards for specific molecule production.
• The development timeline for NCT from idea to pilot scale in under a year is presented as a key differentiator compared to the years of trial and error often associated with enzyme development in the industry.
• The company's intellectual property strategy, with over 30 issued and 40 pending patents, is a common and important practice in the biotech industry to protect novel technologies and processes.

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened litigation that would have a material adverse effect on its business, operating results, cash flows, or financial condition.

Related Party Transactions

• The company had outstanding payables to MDB Capital Holdings, LLC of $13,224 as of September 30, 2026, and $5,330 as of December 31, 2025.
• MDB Capital Holdings, LLC was a majority owner until the November 2024 IPO, and its holdings were diluted to a 43.50% minority interest as of September 30, 2026.

Stakeholder Impact

• Shareholders: The company's going concern issues and continued net losses may negatively impact shareholder value. Recent capital raises provide some short-term liquidity but also dilute existing shareholders.
• Employees: Increased R&D and G&A costs, including compensation, suggest continued investment in personnel. Stock-based compensation is a significant expense.
• Creditors: The company's ability to meet long-term obligations is uncertain, posing a risk to creditors.
• Partners/Collaborators: Government actions on research grants could indirectly affect partner companies and clients, potentially impacting collaboration efforts.

Next Steps

• Advance the AMBER program (NCT/Tyferyn) through scale-up, GRAS status, and clinical studies.
• Continue scale-up for the SAPPHIRE program (EXOZ003) for joint comfort.
• Advance the AMETHYST program (EXOZ004) for mental stress, focus, and energy.
• Evaluate a women's health program focused on menopause support (EXOZ005).
• Advance pharmaceutical candidates (e.g., NCT analogs) through discovery or lead optimization.
• Seek partnering or exit opportunities for pharmaceutical candidates, generally between IND-enabling studies and Phase 2 clinical trials.
• Continue to pursue non-dilutive funding opportunities, including grants.
• Continue to monitor economic conditions and adjust business and financing plans as needed.

Key Dates

Recommendation

The company's technology platform shows promise, particularly in its lead program NCT, with impressive pilot results. However, the significant net losses, increasing cash burn, and explicit statement of substantial doubt regarding its ability to continue as a going concern present considerable risk. The recent capital raise provides a temporary reprieve, but the long-term viability remains uncertain without achieving profitability or securing further substantial funding. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor future developments closely, particularly regarding funding and progress towards commercialization, before considering a more aggressive stance.

Keywords

synthetic biology, cell-free, exozymes, N-trans-caffeoyltyramine, NCT, Tyferyn, biomanufacturing, drug development